17 -2 (52) 2023 — Abdukadirova N.M., Tulaboeva G.M. — PAINFUL CHARACTERISTICS OF COVID-19 INFECTION AND CARDIOVASCULAR DISEASE

PAINFUL CHARACTERISTICS OF COVID-19 INFECTION AND CARDIOVASCULAR DISEASE

Abdukadirova N.M., Center for advanced training of medical personnel

Tulaboeva G.M., Center for advanced training of medical personnel

Kh.M. Sagatova, Center for advanced training of medical personnel

Khashimov A.A., Center for advanced training of medical personnel

Achilov F.K. Center for advanced training of medical personnel

Resume

The article is devoted to a review of data on the prevalence and effect of cardiovascular diseases on the course and outcomes of the new corona virus infection COVID-19. The results of the analysis of the latest literature data on the safety of taking angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers are presented.  myocardial injury in COVID-19.  The issue of organizing rehabilitation assistance to patients is under consideration, СOVID – 19.     

 Keywords: coronavirus, COVID-19, cardiovascular diseases, angiotensin-converting enzyme inhibitors, angiotensin receptor antagonists, arterial hypertension, acute myocardial injury, rehabilitation.

First page

92

Last page

98

For citation: Abdukadirova N.M., Tulaboeva G.M., Kh.M. Sagatova, Khashimov A.A., Achilov F.K. PAINFUL CHARACTERISTICS OF COVID-19 INFECTION AND CARDIOVASCULAR DISEASE //New Day in Medicine 2(52)2023 92-98 https://clck.ru/33X53j

LIST OF REFERENCES:

1. Sun X., Wang T., Cai D., Hu Z., Chen J., Liao H. et. al. Cytokine storm intervention in the early stages of COVID-19 pneumonia. Cytokine & Growth Factor Reviews. 2020; 53:38-42. 
2. World Health Organization. Clinical management of COVID-19. WHO Reference Number: WHO/2019-nCoV/clinical/2020.5. 2020. [Internet] 2020.
3. Министерство здравоохранения РФ. Временные методические рекомендации «Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19)». Версия 7 (03.06.2020). Москва.
4. Tobaiqy M., Qashqary M., Al-Dahery S., Mujallad A., Hershan A.A., Kamal M.A. et al. Therapeutic management of patients with COVID-19: a systematic review. Infection Prevention in Practice. 2020;100061.
5. Darmon P., Dadoun F., Boullu-Ciocca S., Grino M., Alessi M-C., Dutour A. Insulin resistance induced by hydrocortisone is increased in patients with abdominal obesity. American Journal of Physiology-Endocrinology and Metabolism. 2006;291(5): E995-1002. 
6. Zarković M., Beleslin B., Ćirić J., Penezić Z., Stojković M., Trbojević B. et. al. Glucocorticoid effect on insulin sensitivity: A time frame. Journal of Endocrinological Investigation. 2008;31(3):238-42.
7. Clore J., Thurby-Hay L. Glucocorticoid-Induced Hyperglycemia. Endocrine Practice. 2009;15(5):469-74. 
8. Shono A., Mori S., Nakamura K., Yatomi A., Takada H., Tanaka H. et. al. Glucocorticoid-sensitive Paroxysmal Atrial Fibrillation, Sick Sinus Syndrome, and Mitral Regurgitation in a Patient with Malignant Rheumatoid Vasculitis. Internal Medicine (Tokyo, Japan). 2019;58(21):3093-8. 
9. Wright F.L., Vogler T.O., Moore E.E., Moore H.B., Wohlauer M.V., Urban S. et. al. Fibrinolysis Shutdown Correlates to Thromboembolic Events in Severe COVID-19 Infection. Journal of the American College of Surgeons. 2020; S1072-7515(20)30400-2.
10. `Tang N., Li D., Wang X., Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. Journal of Thrombosis and Haemostasis. 2020;18(4):844-7. 
11. Thachil J., Tang N., Gando S., Falanga A., Cattaneo M., Levi M. et al. ISTH interim guidance on recognition and management of coagulopathy in COVID‐19. Journal of Thrombosis and Haemostasis. 2020;18(5):1023-6. 
12. Liao X., Wang B., Kang Y. Novel coronavirus infection during the 2019-2020 epidemic: preparing intensive care units – the experience in Sichuan Province, China. Intensive Care Medicine. 2020;46(2):357-60. 
13. The OpenSAFELY Collaborative, Williamson E., Walker A.J., Bhaskaran K.J., Bacon S., Bates C. et al. OpenSAFELY: factors associated with COVID-19-related hospital death in the linked electronic health records of 17 million adult NHS patients. Epidemiology. 2020.
14. Schett G., Sticherling M., Neurath M.F. COVID-19: risk for cytokine targeting in chronic inflammatory diseases? Nature Reviews Immunology. 2020; 20(5):271-2. 
15. Mehta P., McAuley D.F., Brown M., Sanchez E., Tattersall R.S., Manson J.J. COVID-19: consider cytokine storm syndromes and immunosuppression. The Lancet. 2020;395(10229):1033-4. 
16. Xu X., Han M., Li T., Sun W., Wang D., Fu B. et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proceedings of the National Academy of Sciences. 2020;117(20):10970-5. 
17. Ucciferri C., Auricchio A., Di Nicola M., Potere N., Abbate A., Cipollone F. et al. Canakinumab in a subgroup of patients with COVID-19. The Lancet Rheumatology. 2020;
18. Wan M.T., Shin D.B., Winthrop K.L., Gelfand J.M. The risk of respiratory tract infections and symptoms in psoriasis patients treated with IL-17-pathway inhibiting biologics: A meta-estimate of pivotal trials relevant to decision-making during the COVID-19 pandemic. Journal of the American Academy of Dermatology. 2020; S0190962220308665.
19. Cao Y., Wei J., Zou L., Jiang T., Wang G., Chen L. et al. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial. Journal of Allergy and Clinical Immunology. 2020; S0091674920307387.
20. Li H., Chen C., Hu F., Wang J., Zhao Q., Gale R.P. et al. Impact of corticosteroid therapy on outcomes of persons with SARS-CoV-2, SARSCoV, or MERS-CoV infection: a systematic review and meta-analysis. Leukemia. 2020;34(6):1503- 11.